Unlock Synergy Xentria Meitheal for Unmatched Collaboration

Xentria Inc./Meitheal. Pharmaceuticals Inc. In clinical trials. Molecule. Innovator product (company) Biosimilars. Company. Status. Omalizumab. Xolair® ( ... In addition, Victoria is the General Counsel & Corporate Secretary of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was ... In June we entered a commercial agreement for XTMAB-16 with Meitheal Pharmaceuticals. Xentria received an up-front payment of $60 million ... The European Medicines Agency (EMA) has granted XTMAB-16, Xentria's ... Earlier this year, Xentria entered into an agreement with Meitheal ... Chicago, IL – September 21, 2023 – Meitheal Pharmaceuticals, Inc. (Meitheal), a fully integrated biopharmaceutical company based in Chicago ... 2023 - 2024 Associate Director, Human Resources @ Xentria, Inc. 2020 - 2022 Corporate Recruiter - Human Resources Manager @ Meitheal Pharmaceuticals, Inc. see ... ... Meitheal Pharmaceuticals, Inc.(以下简称“Meitheal”“被许可方”)拟与Xentria签署《许可、开发与商业化协议》(以下简称《许可协议》)，Xentria授予被 ... Xentria Secures Landmark Agreement with NYU for Cardiovascular Therapy Development ... The Growing Crisis of Antimicrobial Resistance: Meitheal ... In a significant ... Front. Pharmacol. 14, 1066454 (2023). 2. Licensing Agreement to Commercialize XTMAB-16 in. Sarcoidosis | XENTRIA & Meitheal Pharmaceuticals. 健友股份公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方在 ...